PPARγ targeted oral cancer treatment and additional utility of genomics analytic techniques.

ABSTRACT:

Objective

Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to have anti-proliferative, anti-angiogenic, and proapoptotic effects, leading to interest in their use as cancer therapeutics. Pioglitazone, a U.S. Food and Drug Administration-approved type II diabetes medication and PPARγ agonist, may have a role in adjuvant head-and-neck squamous cell carcinoma treatment or prevention. Therefore, the purpose of this study was: 1) to treat oral cavity cancer cells with the PPARγ activator, pioglitazone, to analyze gene expression changes; and 2) to compare those changes with our preexisting genomic data for development of hypothesis-driven additional basic and clinical studies.

Study design

Prospective in vitro.

Methods

We utilized microarray te

SUBMITTER: Handley N 

PROVIDER: S-EPMC5360511 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature